Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699

PHASE2CompletedINTERVENTIONAL
Enrollment

127

Participants

Timeline

Start Date

October 5, 2018

Primary Completion Date

November 16, 2023

Study Completion Date

November 16, 2023

Conditions
Cushing's Syndrome
Interventions
DRUG

osilodrostat

osilodrostat, in the form of film coated tablets for oral administration, in the following tablet strengths: 1mg, 5mg, 10mg. Each strength has unique tablet size, colour and imprint.

Trial Locations (56)

1431

USHATE Akad Ivan Penchev, Sofia

3000

Gasthuisberg University Hospital, Leuven

10032

Columbia University Medical Center New York Presbyterian Neuroendocrine Unit, New York

10065

Memorial Sloan Kettering Cancer Center, New York

10330

King Chulalongkorn Memorial Hospital, Bangkok

10700

Siriraj Hospital, Bangkok

15006

Complejo Uni. Hosp. A Coruña ( antes Hospital Juan Canalejo), A Coruña

19104

University of Pennsylvania Medical Center Univ Penn, Philadelphia

28009

Hospital Gregorio Maranon, Madrid

30322

Emory University School of Medicine G2304 - C2301, Atlanta

33604

CHU de Bordeaux, Pessac

34098

Istanbul University Cerrahpasa Faculty of Medicine, Istanbul

34662

Marmara University Medical Faculty, Altunizade

35128

Azienda Ospedaliera di Padova Università degli Studi, Padua

41013

Hospital Universitario Virgen del Rocio, Seville

41380

Kocaeli University Medical Faculty, Kocaeli

44195

Cleveland Clinic Foundation, Cleveland

46026

Hospital Universitario i Politecnico La Fe, Valencia

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

53226

Medical College of Wisconsin MCW 2, Milwaukee

56124

Az Ospedaliero Universitaria Pisana Pres Osped di Cisanello, Pisa

59037

CHRU de Lille, Lille

60126

AOU Osp Riuniti Umberto I GM Lancisi G Salesi Univ Studi, Ancona

60611

Northwestern University SC - LCI699C2301, Chicago

75014

Hopital Cochin, Paris

80045

University of Colorado, Aurora

80131

A O Universitaria Policlinico Federico II Univ Studi Fed II, Napoli

81377

Universitaetsklinikum Muenchen LMU, München

90110

Songklanagarind Hospital Endocrinology and Metabolism, Songkhla

91054

Universitaetsklinikum Erlangen Nuernberg, Erlangen

94275

Hopital Kremlin Bicetre, Le Kremlin-Bicêtre

97239

Oregon Health and Science University, Portland

100034

Peking University First Hospital, Beijing

100730

Peking Union Medical College Hospital, Beijing

110029

All India Institute of Medical Sciences, New Delhi

117036

Center for Endocrinology Russian Academy of Med Sciences, Moscow

510080

The First Affiliated Hopsital, Sun Yat-Sun University, Guangzhou

610041

West China Hospital of Sichuan University, Chengdu

C1180AAX

Sanatorio Guemes, CABA

A-1090

Universitaetsklinik fuer Innere Medizin III, Vienna

60020-181

Universidade Federal do Ceara, Fortaleza

21941-913

Hospital Universitario Clementino Fraga Filho, Rio de Janeiro

04039 004

Hospital do Servidor Publico Estadual de Sao Paulo, São Paulo

05403 000

Hospital das Clinicas da Faculdade de Medicina da USP, São Paulo

T6G 2B7

University of Alberta Hospital, Edmonton

B3H 1V7

QEII Health Sciences Centre, Halifax

H2W 1T8

Centre de recherche du CHUM CRCHUM, Montreal

J1H 5N4

CHUS Hopital Fleurimont, Sherbrooke

1406 1200

Clinica Los Yoses, San Pedro

460-0001

National Hospital Organization Nagoya Medical Center, Nagoya

663 8501

Hyogo College of Medicine Hospital, Nishinomiya

3015 GD

Erasmus MC, Rotterdam

31-501

SP ZOZ Szpital Uniwersytecki w Krakowie, Krakow

03 242

Mazowiecki Szpital Brodnowski, Warsaw

03080

Seoul National University Hospital, Seoul

03722

Yonsei Univ Health System YUCM, Seoul

All Listed Sponsors
lead

RECORDATI GROUP

INDUSTRY

NCT03606408 - Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699 | Biotech Hunter | Biotech Hunter